Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

RETA GLP-3Check methods and identity

What the first TRANSCEND diabetes trial measured

2 numbered sourcesSource years 2026

Peptides are short chains of amino acids held together by peptide bonds. They can engage receptors that affect how the body handles glucose. Retatrutide is an investigational peptide that acts at GIP, GLP-1 and glucagon receptors. The catalog’s “GLP-3” wording describes this entry rather than a receptor. The 2026 TRANSCEND-T2D-1 trial examined a specific group of adults with type 2 diabetes whose glucose was above target with diet and exercise alone. [1]

The trial randomized 537 participants to one of three retatrutide groups or placebo. The investigators recorded changes in HbA1c at 40 weeks. HbA1c measures how much glucose is attached to hemoglobin, giving an estimate of blood sugar exposure over the previous months. This differs from one fasting glucose test, which reflects the concentration at a particular time. HbA1c helped the researchers measure the effect of the tested assignments over the trial period. [1]

The three retatrutide groups had average HbA1c decreases of 1.69, 1.86 and 1.94 percentage points, compared with 0.81 percentage points with placebo. The differences from placebo ranged from 0.88 to 1.12 percentage points. It is important to keep both the change from baseline and the comparison with placebo in view. Some change also occurred in the placebo group. The randomized contrast estimates the difference associated with assignment to retatrutide under the study conditions. [1]

The study also measured weight and adverse events. An improvement on the glucose measure provides evidence for that outcome. Other measures describe separate parts of the experience, such as whether weight changed and which symptoms were reported during treatment. A 40-week study can establish a comparative result for the planned interval. It provides less information about rare adverse effects or complications that take years to develop. [1]

This trial enrolled people whose glucose management at baseline relied on diet and exercise. TRIUMPH-2 also enrolled people with type 2 diabetes but included many participants who already took glucose-lowering medicines and used weight change as the main outcome. These different designs help explain why diabetes research on one peptide may include more than one large trial. TRANSCEND-T2D-1 addresses glucose control under its own entry criteria and comparator. It does not establish an approved diabetes indication or provide a result for combinations that the investigators did not assign. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop RETA GLP-3

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.